Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;43(7):1475-1480.
doi: 10.1007/s10096-024-04849-0. Epub 2024 May 16.

Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature

Barthelemy Lafon-Desmurs  1 , Benoit Gachet  2   3 , Benjamin Hennart  4 , Benjamin Valentin  5 , Gabrielle Roosen  6 , Maxime Degrendel  2 , Caroline Loiez  7 , Eric Beltrand  8 , Piervito D'Elia  9 , Henri Migaud  10 , Olivier Robineau  2   3   11 , Eric Senneville  2
Affiliations
Review

Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature

Barthelemy Lafon-Desmurs et al. Eur J Clin Microbiol Infect Dis. 2024 Jul.

Abstract

Implant-related infections may need suppressive antibiotic therapy (SAT). We describe a SAT strategy using dalbavancin with therapeutic drug monitoring (TDM). This is a retrospective bicentric study of patients with implant-related infection who received dalbavancin SAT between January 2021 and September 2023. Fifteen patients were included. Median number of injections was 4 (IQR: 2-7). Median time between two reinjections was 57 days (IQR 28-82). Dalbavancin plasma concentrations were above 4 mg/L for 97.9% of dosages (93/95) and above 8 mg/L for 85% (81/95). These results support the use of dalbavancin SAT for implant-related infections.

Keywords: Dalbavancin; Dosage; Prosthetic joint infection; Suppressive therapy; Vascular graft infection.

PubMed Disclaimer

References

    1. Smeds MR, Duncan AA, Harlander-Locke MP, Lawrence PF, Lyden S, Fatima J et al (2016) Treatment and outcomes of aortic endograft infection. J Vasc Surg févr 63(2):332–340 - DOI
    1. Bosco F, Cacciola G, Giustra F, Risitano S, Capella M, Vezza D, Barberis L, Cavaliere P, Massè A, Sabatini L (2023) Characterizing recurrent infections after one-stage revision for periprosthetic joint infection of the knee: a systematic review of the literature. Eur J Orthop Surg Traumatol 33(7):2703–2715. https://doi.org/10.1007/s00590-023-03480-7 - DOI - PubMed - PMC
    1. Zhang C, Liu Z, Lin Y, Cai Y, Zhang X, Huang Z et al (2022) Patient-reported outcome on quality of life and pain after revision arthroplasty for periprosthetic joint infection: A cross-sectional study. J Clin Med 11(23):7182 - DOI - PubMed - PMC
    1. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM et al (2013) Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis janv 56(1):e1-25 - DOI
    1. Pouderoux C, Becker A, Goutelle S, Lustig S, Triffault-Fillit C, Daoud F et al (2019) Subcutaneous suppressive antibiotic therapy for bone and joint infections: safety and outcome in a cohort of 10 patients. J Antimicrob Chemother 74(7):2060–4 - DOI - PubMed

LinkOut - more resources